Rain Cage partnership aims to revolutionize medical imaging

Calgary, Canada – TheNewswire – May 24, 2023 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (“Voyageur” or the “Corporation”), announces it has entered into a groundbreaking development and license agreement with Rain Cage Carbon Inc. (“Rain Cage”). This strategic partnership aims to revolutionize the field by developing and manufacturing cutting-edge nanocarbon/fullerene-based contrast agents for medical imaging, utilizing Rain Cage’s innovative EDEN™ carbon capture technology.

By harnessing the unique properties of nanocarbons produced by the EDEN™ system, Voyageur is committed to creating safer and more advanced contrast agents for medical imaging. The encapsulation and transporting of contrast agents within nanocarbons will significantly enhance efficacy and safety for patients. Rain Cage is currently developing multiple molecules for contrast imaging, and through this agreement, Voyageur secures the rights to develop fullerene-based imaging agents for the United States and Canada initially. Expansion plans worldwide are expected to follow as development milestones are achieved and production capacity increases.